文献速递胸部肿瘤支持与姑息治疗

添加免疫检查点抑制剂增加实体瘤患者肺炎风险:III期随机对照试验荟萃分析

The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
PubMed 文献 · Eur J Cancer · 2021-04-24

该荟萃分析纳入25项III期随机对照试验共16,343例患者,评估在常规治疗基础上添加免疫检查点抑制剂(ICI)对实体瘤患者肺炎风险的影响。结果显示,添加ICI显著增加任何级别肺炎(OR 2.67,95%CI 2.12-3.37)及III-V级肺炎(OR 1.83,95%CI 1.26-2.65),且不受ICI作用机制和癌种影响。

要点

  • 添加ICI使任何级别肺炎风险增至2.67倍(OR 2.67,95%CI 2.12-3.37)。
  • 添加ICI使III-V级肺炎风险增至1.83倍(OR 1.83,95%CI 1.26-2.65)。
  • 亚组分析显示ICI机制和癌种(肺癌与非肺癌)间异质性无显著差异。

核心结论

  • 在实体瘤常规治疗中添加ICI显著增加任何级别和III-V级肺炎风险,且不受ICI作用机制和癌种影响。

研究设计与样本

  • 荟萃分析纳入25项III期随机对照试验,共16,343例患者分析任何级别肺炎,其中23项试验15,006例患者分析III-V级肺炎。

主要发现

  • 添加ICI组任何级别肺炎的OR为2.67(95%CI 2.12-3.37)。
  • 添加ICI组III-V级肺炎的OR为1.83(95%CI 1.26-2.65)。
  • 基于ICI作用机制、癌种(肺癌与非肺癌)及各ICI的亚组分析中未观察到显著异质性差异。

临床怎么用

  • 肿瘤内科医生在使用ICI时应评估患者肺炎风险,尤其对已知肺炎危险因素或间质性肺病患者需谨慎选择治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become one of the standard treatment options for solid tumours; however, treatment-related adverse events, including pneumonitis, sometimes disrupt the ongoing treatment. To evaluate the impact of ICI addition on the risk of pneumonitis, a meta-analysis was conducted. METHODS: Phase III randomised controlled trials comparing ICIs and conventional therapy with conventional therapy alone were selected by searching databases, including PubMed, Embase, Web of Science and Cochrane Library. The odds ratio (OR) of any grade and grade III-V pneumonitis was calculated. Meta-analysis was performed to compare the incidence of pneumonitis between the treatment arm with additional ICIs and the arm with conventional therapy. RESULTS: A total of 25 randomised controlled trials (RCTs) representing 16,343 patients for grade I-V and 23 RCTs with 15,006 patients for grade III-V pneumonitis were analysed. Adding ICIs was associated with a significant increase in pneumonitis (grade I-V: OR, 2.67, 95% confidence interval [CI]: 2.12-3.37, grade III-V: OR, 1.83, 95% CI: 1.26-2.65). In subgroup analyses based on the mechanism of action of ICIs, cancer types (lung and non-lung cancer) and each ICI, no significant difference in heterogeneity was observed. CONCLUSIONS: Adding ICIs to the conventional treatment for solid tumours significantly increased both grade I-V and grade III-V pneumonitis regardless of the mechanisms of ICIs and cancer type. These results would be helpful for oncologists to choose the appropriate treatment options using ICIs, particularly for patients with known risk factors of pneumonitis or interstitial lung disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fujiwara Y, Horita N, Namkoong H, et al. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. Eur J Cancer. 2021. PMID: 33906099. doi:10.1016/j.ejca.2021.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。